Replies to post #510 on Intercept Pharmaceuticals (ICPT)

[DewDiligence]

You're preaching to the choir vis-á-vis Ocaliva. I'm bearish on the REGENERATE trial, and have said so numerous times.

On the other hand, newer and better FXR agonists do not seem to have the side-effect baggage that comes with Ocaliva. I'm bullish on ENTA's NASH compound, EDP-305. (I'm long ENTA.)